TABLE 3

Adverse events of any cause and any severity occurring with pyronaridine-artesunate treatment of P. falciparum malaria across three study sites in western Cambodiaa

Adverse eventNo. (%) of patients with adverse event (n = 123) on day:
0+1+
Headache100 (81.3)2 (1.6)
Vertigo85 (69.1)0
Insomnia64 (52.0)0
Abdominal pain55 (44.7)6 (4.9)
Tinnitus55 (44.7)2 (1.6)
Nausea33 (26.8)2 (1.6)
Palpitation22 (17.9)0
Diarrhea16 (13.0)2 (1.6)
Vomiting10 (8.1)1 (0.8)
Itching10 (8.1)5 (4.1)
Deafness7 (5.7)1 (0.8)
Tachycardia6 (4.9)0
Rash3 (2.4)1 (0.8)
Dark urine3 (2.4)0
Abdominal bleeding2 (1.6)1 (0.8)
Confusion1 (0.8)0
Other1 (0.8)0
  • a 0+ includes all adverse events recorded at day 0, and 1+ includes those recorded at day 1.